Jeffrey Yordon - 03 Aug 2021 Form 4 Insider Report for Athenex, Inc.

Role
COO, and President, Athenex Pharmaceutical Division.
Signature
/s/ Teresa Bair, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Aug 2021
Net transactions value
$0
Form type
4
Filing time
05 Aug 2021, 16:49:25 UTC
Next filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 237,106 03 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 03 Aug 2021 Common Stock 50,000 $3.80 Direct F3
transaction ATNXQ Restricted Stock Units Award $0 +50,000 $0.000000 50,000 03 Aug 2021 Common Stock 50,000 Direct F4, F5
holding ATNXQ Stock Option (Right to Buy) 150,000 03 Aug 2021 Common Stock 150,000 $9.00 Direct
holding ATNXQ Stock Option (Right to Buy) 211,820 03 Aug 2021 Common Stock 211,820 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 100,000 03 Aug 2021 Common Stock 100,000 $17.30 Direct F1
holding ATNXQ Stock Option (Right to Buy) 100,000 03 Aug 2021 Common Stock 100,000 $13.17 Direct F2
holding ATNXQ Stock Option (Right to Buy) 100,000 03 Aug 2021 Common Stock 100,000 $12.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on March 27, 2019.
F2 This option vests in four equal annual installments beginning on February 28, 2020.
F3 This option vests in four equal annual installments beginning on August 3, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.

Remarks:

COO, and President, Athenex Pharmaceutical Division.